GLP-1 Pipeline 2026 in Australia (Research)

The short answer

The GLP-1 pipeline describes the group of investigational metabolic compounds that pharmaceutical companies are studying in clinical trials, beyond the medicines already on the market. As of October 2026, the most discussed next-wave candidates include retatrutide, CagriSema, amycretin, orforglipron, MariTide (maridebart cafraglutide) and survodutide. These differ by mechanism, for example triple hormone agonists, amylin plus GLP-1 combinations, oral non-peptide agonists, a GIP-antagonist plus GLP-1 design, and GLP-1 plus glucagon dual agonists. Most of these candidates are not registered on the Australian Register of Therapeutic Goods (ARTG) and are supplied by NovaPeptides for laboratory research use only. This page is an information hub that links the individual compound guides and makes no efficacy or outcome claims.

What "pipeline" and trial phases mean

A drug pipeline is the sequence of research stages a candidate moves through before any regulator might consider it for registration. Understanding the phase labels helps put the compounds below in context, because being "in the pipeline" is very different from being an approved medicine.

Common clinical trial phases

• Preclinical: laboratory and animal research, before any human studies.
• Phase 1: first studies in small groups, focused on safety and how a compound is handled by the body.
• Phase 2: larger studies that continue to assess safety and gather early signals in a target population.
• Phase 3: large, pivotal studies that regulators typically require before considering registration.
• Registration and post-market: regulatory review, and if registered, ongoing monitoring.

A compound reported to be "in Phase 3" has not necessarily completed those studies, and completing a trial is not the same as being approved in any given country. Approval in one jurisdiction, such as the United States, does not mean a product is registered in Australia.

Triple agonists: retatrutide

Retatrutide (developed by Eli Lilly) is described as an investigational triple hormone receptor agonist that acts on the GIP, GLP-1 and glucagon receptors. It is the headline example of the "triple agonist" class and is given attention in the research community because it combines three mechanisms in a single molecule.

As of October 2026, retatrutide has been reported in Phase 3 studies, with its developer indicating plans to pursue global regulatory submissions. It is not registered on the ARTG in Australia. NovaPeptides supplies retatrutide as a research chemical for laboratory use only, and this page makes no claim about efficacy or outcomes.

Amylin combinations: CagriSema and amycretin

Novo Nordisk is studying two candidates that engage the amylin pathway alongside GLP-1 signalling, which is why they are often grouped together.

The two amylin-linked candidates

• CagriSema: a combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist), studied as a once-weekly injectable. Reported in Phase 3 programs as of 2026.
• Amycretin: a single molecule designed to act on both amylin and GLP-1 pathways, reported to be advancing into Phase 3 in both subcutaneous and oral forms as of 2026.

Neither CagriSema nor amycretin is registered on the ARTG in Australia. Both are supplied by NovaPeptides for laboratory research use only. We make no efficacy or outcome claims about either candidate.

Oral candidates: orforglipron

Orforglipron (developed by Eli Lilly) is described as a small-molecule, non-peptide GLP-1 receptor agonist. Its interest to researchers lies in being an orally administered candidate rather than an injectable, which is unusual for the GLP-1 class.

Regulatory status differs by country and changes over time. As of 2026, orforglipron has been reported to progress through a Phase 3 program and to have received regulatory approval in the United States for weight management, reported under the brand name Foundayo. That is a United States development; as of October 2026 it is not registered on the ARTG in Australia. NovaPeptides supplies orforglipron for laboratory research use only, and nothing here should be read as a therapeutic or efficacy claim.

GIP-antagonist and dual glucagon designs: MariTide and survodutide

Two further candidates take distinct mechanistic approaches and are commonly discussed together as part of the next wave.

Two contrasting mechanisms

• MariTide (maridebart cafraglutide, developed by Amgen): described as an antibody-peptide conjugate that acts as a GLP-1 receptor agonist and a GIP receptor antagonist. Reported in an ongoing Phase 3 program as of October 2026.
• Survodutide (developed by Boehringer Ingelheim with Zealand Pharma): described as a GLP-1 and glucagon receptor dual agonist, studied as a once-weekly injectable. Reported in Phase 3 studies across obesity, type 2 diabetes and liver-related research as of 2026.

Neither MariTide nor survodutide is registered on the ARTG in Australia. Both are supplied by NovaPeptides for laboratory research use only. This hub reports research stage and mechanism only, with no efficacy or outcome claims.

Australian regulatory status and research-use-only

In Australia, therapeutic goods are listed on the Australian Register of Therapeutic Goods (ARTG), administered by the Therapeutic Goods Administration (TGA). Among the compounds discussed here, two older reference medicines are ARTG-registered Schedule 4 (prescription-only) medicines, which is a factual regulatory distinction and not an endorsement.

ARTG-registered reference medicines (factual, as at October 2026)

• Semaglutide: a GLP-1 receptor agonist, registered in Australia under brands including Ozempic and Wegovy, Schedule 4 prescription-only.
• Tirzepatide: a GIP and GLP-1 receptor dual agonist, registered in Australia as Mounjaro, Schedule 4 prescription-only.

By contrast, the next-wave pipeline candidates on this page, retatrutide, CagriSema, amycretin, orforglipron, MariTide and survodutide, are not registered on the ARTG as of October 2026. NovaPeptides supplies these as research chemicals for laboratory and research use only. They are not for human or veterinary use, are not approved medicines in Australia, and nothing on this page should be interpreted as medical advice or a recommendation to use any substance in or on the body.

How NovaPeptides supplies research peptides

NovaPeptides is an Australian supplier of research peptides and related research chemicals intended for laboratory use only. Our role is to make compounds available to researchers, with clear, neutral information about what each compound is and where it currently sits in the development pipeline.

What this hub does and does not do

• It summarises developer, mechanism class and reported trial stage for each candidate, in neutral terms.
• It notes Australian regulatory status, including which reference medicines are ARTG-registered and which candidates are not.
• It links to the individual compound guides for readers who want more detail on a single candidate.
• It does not provide dosing, protocols, efficacy claims or any guidance on human use.

Pipeline status is a snapshot of research, not a promise of availability or outcome. Always verify current regulatory status before acting on anything you read.

Frequently asked questions